Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

Abstract Background Antibody-mediated rejection (ABMR) is a cardinal cause of renal allograft loss. This rejection type, which may occur at any time after transplantation, commonly presents as a continuum of microvascular inflammation (MVI) culminating in chronic tissue injury. While the clinical re...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Katharina A. Mayer, Klemens Budde, Philip F. Halloran, Konstantin Doberer, Lionel Rostaing, Farsad Eskandary, Anna Christamentl, Markus Wahrmann, Heinz Regele, Sabine Schranz, Sarah Ely, Christa Firbas, Christian Schörgenhofer, Alexander Kainz, Alexandre Loupy, Stefan Härtle, Rainer Boxhammer, Bernd Jilma, Georg A. Böhmig
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2022-04-01
سلاسل:	Trials
الموضوعات:	Antibody-mediated rejection CD38 Donor-specific antibody Felzartamab Kidney transplantation Monoclonal antibody
الوصول للمادة أونلاين:	https://doi.org/10.1186/s13063-022-06198-9
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!